

Keith A A Fox

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2461631/publications.pdf>

Version: 2024-02-01

240
papers

62,069
citations

4831

87
h-index

1256

232
g-index

247
all docs

247
docs citations

247
times ranked

34539
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 883-891.	13.9	8,006
2	Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. <i>Lancet</i> , The, 2001, 358, 527-533.	6.3	2,914
3	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	1.0	2,687
4	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. <i>New England Journal of Medicine</i> , 2006, 354, 1706-1717.	13.9	2,582
5	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. <i>European Heart Journal</i> , 2008, 29, 2909-2945.	1.0	2,128
6	Predictors of Hospital Mortality in the Global Registry of Acute Coronary Events. <i>Archives of Internal Medicine</i> , 2003, 163, 2345.	4.3	1,856
7	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	13.9	1,745
8	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. <i>European Heart Journal</i> , 2007, 28, 1598-1660.	1.0	1,699
9	Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 366, 9-19.	13.9	1,681
10	A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease. <i>New England Journal of Medicine</i> , 1997, 337, 447-452.	13.9	1,397
11	A Validated Prediction Model for All Forms of Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 2727.	3.8	1,344
12	Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). <i>BMJ: British Medical Journal</i> , 2006, 333, 1091.	2.4	1,236
13	Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2006, 114, 774-782.	1.6	1,196
14	Management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2003, 24, 28-66.	1.0	1,188
15	Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2006, 354, 1464-1476.	13.9	1,104
16	Prospective Study of Heart Rate Variability and Mortality in Chronic Heart Failure. <i>Circulation</i> , 1998, 98, 1510-1516.	1.6	1,057
17	Vorapaxar in the Secondary Prevention of Atherothrombotic Events. <i>New England Journal of Medicine</i> , 2012, 366, 1404-1413.	13.9	841
18	Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1519-1530.	3.8	830

#	ARTICLE	IF	CITATIONS
19	Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Nonâ€“ST-Elevation Acute Coronary Syndrome. <i>Circulation</i> , 2004, 110, 1202-1208.	1.6	778
20	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. <i>New England Journal of Medicine</i> , 2012, 367, 1297-1309.	13.9	765
21	Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2002, 23, 1809-1840.	1.0	764
22	Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1982-1988.	1.2	752
23	Early versus Delayed Invasive Intervention in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2009, 360, 2165-2175.	13.9	748
24	Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1892.	3.8	744
25	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. <i>Lancet, The</i> , 2010, 376, 1233-1243.	6.3	725
26	Routine vs Selective Invasive Strategies in Patients With Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 2908.	3.8	717
27	Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2003, 108, 1682-1687.	1.6	682
28	Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2010, 363, 930-942.	13.9	681
29	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 219-229.	6.3	651
30	International Day for the Evaluation of Abdominal Obesity (IDEA). <i>Circulation</i> , 2007, 116, 1942-1951.	1.6	599
31	Association of Diet, Exercise, and Smoking Modification With Risk of Early Cardiovascular Events After Acute Coronary Syndromes. <i>Circulation</i> , 2010, 121, 750-758.	1.6	556
32	Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. <i>European Heart Journal</i> , 2011, 32, 2387-2394.	1.0	536
33	Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE)**Further information about the project, along with a complete list of the study participants, can be found at www.outcomes.org/grace . <i>American Journal of Cardiology</i> , 2002, 90, 358-363.	0.7	534
34	Long-Term Outcome of a Routine Versus Selective Invasive Strategy in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2435-2445.	1.2	515
35	Effects of <i>CYP2C19</i> Genotype on Outcomes of Clopidogrel Treatment. <i>New England Journal of Medicine</i> , 2010, 363, 1704-1714.	13.9	497
36	Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2013, 127, 224-232.	1.6	463

#	ARTICLE	IF	CITATIONS
37	Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome. <i>Circulation</i> , 2009, 119, 2877-2885.	1.6	428
38	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2018, 391, 205-218.	6.3	426
39	Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE) Tj ETQq1 1 0.784314 rgBT /Over 361	1.0	361
40	Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Circulation</i> , 2014, 130, 138-146.	1.6	345
41	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011, 32, 1854-1864.	1.0	343
42	High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. <i>BMJ</i> , The, 2015, 350, g7873.	3.0	338
43	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <i>Gastroenterology</i> , 2019, 157, 682-691.e2.	0.6	299
44	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2306-2315.	1.2	296
45	Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2003, 107, 966-972.	1.6	285
46	Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. <i>BMJ Open</i> , 2014, 4, e004425.	0.8	273
47	High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. <i>Lancet</i> , The, 2018, 392, 919-928.	6.3	263
48	Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1742-1751.	1.2	253
49	Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1998-2006.	1.2	240
50	Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. <i>European Heart Journal</i> , 2008, 29, 609-617.	1.0	233
51	From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes The Global Registry of Acute Coronary Events (GRACE). <i>European Heart Journal</i> , 2003, 24, 1414-1424.	1.0	225
52	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>European Heart Journal</i> , 2016, 37, 2882-2889.	1.0	222
53	Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease. <i>Circulation</i> , 2010, 121, 2575-2583.	1.6	218
54	Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction?. <i>Circulation</i> , 2007, 116, 2793-2801.	1.6	213

#	ARTICLE	IF	CITATIONS
55	Factors Associated With Major Bleeding Events. <i>Journal of the American College of Cardiology</i> , 2014, 63, 891-900.	1.2	212
56	Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid. <i>Circulation</i> , 2008, 118, 1705-1712.	1.6	210
57	Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1785.	3.8	200
58	Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1591.	3.8	190
59	Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban. <i>Stroke</i> , 2014, 45, 1304-1312.	1.0	187
60	Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 651-658.	1.2	181
61	Association of Statin Therapy with Outcomes of Acute Coronary Syndromes: The GRACE Study. <i>Annals of Internal Medicine</i> , 2004, 140, 857.	2.0	178
62	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015, 36, ehv304.	1.0	175
63	β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2710-2720.	1.2	174
64	Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (The Global Registry of Acute Coronary Events [GRACE]). <i>American Journal of Cardiology</i> , 2004, 93, 288-293.	0.7	165
65	The expanded Global Registry of Acute Coronary Events: Baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. <i>American Heart Journal</i> , 2009, 158, 193-201.e5.	1.2	165
66	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. <i>American Heart Journal</i> , 2017, 194, 132-140.	1.2	161
67	Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease—A list of participating ESSENCE Study Group investigators may be found in <i>N Engl J Med</i> 1997;337:447-52. <i>Journal of the American College of Cardiology</i> , 2000, 36, 693-698.	1.2	154
68	Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. <i>European Heart Journal</i> , 2008, 30, 655-661.	1.0	149
69	Ultrasmall Superparamagnetic Particles of Iron Oxide in Patients With Acute Myocardial Infarction. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 559-565.	1.3	148
70	Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial. <i>Stroke</i> , 2014, 45, 1739-1747.	1.0	142
71	Design and rationale of CURRENT-OASIS 7: A randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. <i>American Heart Journal</i> , 2008, 156, 1080-1088.e1.	1.2	140
72	On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin. <i>Circulation</i> , 2016, 134, 37-47.	1.6	134

#	ARTICLE	IF	CITATIONS
73	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Canadian Journal of Cardiology, 2017, 33, 1027-1035.	0.8	133
74	Safety of the oral factor Xla inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet, The, 2022, 399, 1383-1390.	6.3	131
75	Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization. Circulation, 2013, 128, 823-833.	1.6	130
76	High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction. Circulation, 2020, 141, 161-171.	1.6	124
77	Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: The Targeted platelet Inhibition to clarify the Optimal strategy to medically manage Acute Coronary Syndromes (TRILOGY) Trial. JAMA, 2013, 309, 1031-1041.	1.3	120
78	Stroke Outcomes in the COMPASS Trial. Circulation, 2019, 139, 1134-1145.	1.6	118
79	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation, 2022, 145, 242-255.	1.6	118
80	Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients. BMJ: British Medical Journal, 2005, 331, 869.	2.4	115
81	Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. European Heart Journal, 2008, 30, 900-907.	1.0	115
82	Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention. Circulation, 2005, 111, 1390-1397.	1.6	113
83	Quality indicators for acute myocardial infarction: A position paper of the Acute Cardiovascular Care Association. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 34-59.	0.4	109
84	Pantoprazole to Prevent Gastrointestinal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology, 2019, 157, 403-412.e5.	0.6	108
85	Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a collaborative analysis of individual data from the FRISC II - ICTUS - RITA-3 (FIR) trials. Heart, 2012, 98, 207-213.	1.2	104
86	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. Circulation, 2021, 143, 2129-2142.	1.6	101
87	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. Journal of the American College of Cardiology, 2019, 73, 3271-3280.	1.2	95
88	Long-Term Cardiovascular Mortality After Procedure-Related or Spontaneous Myocardial Infarction in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Circulation, 2012, 125, 568-576.	1.6	94
89	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open, 2017, 7, e017157.	0.8	92
90	An Invasive or Conservative Strategy in Patients With Diabetes Mellitus and Non-ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2012, 60, 106-111.	1.2	91

#	ARTICLE	IF	CITATIONS
91	The myth of "stable" coronary artery disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 9-21.	6.1	89
92	The Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 Trial. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2249-2255.	1.2	87
93	Performance of hospitals according to the ESC ACCA quality indicators and 30-day mortality for acute myocardial infarction: national cohort study using the United Kingdom Myocardial Ischaemia National Audit Project (MINAP) register. <i>European Heart Journal</i> , 2017, 38, 974-982.	1.0	87
94	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	6.1	87
95	Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. <i>Circulation</i> , 2017, 135, 323-333.	1.6	86
96	Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2007, 147, 304.	2.0	85
97	β ₂ -Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 872-881.	0.9	84
98	Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2005, 149, 217-226.	1.2	83
99	The COMPASS Trial. <i>Circulation</i> , 2020, 142, 40-48.	1.6	83
100	Multimorbidity and survival for patients with acute myocardial infarction in England and Wales: Latent class analysis of a nationwide population-based cohort. <i>PLoS Medicine</i> , 2018, 15, e1002501.	3.9	82
101	Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. <i>European Heart Journal</i> , 2010, 31, 50-58.	1.0	81
102	Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. <i>American Journal of Medicine</i> , 2015, 128, 766-775.	0.6	81
103	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. <i>Circulation</i> , 2019, 140, 529-537.	1.6	81
104	Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. <i>Europace</i> , 2018, 20, 1-11.	0.7	80
105	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. <i>PLoS ONE</i> , 2018, 13, e0191592.	1.1	80
106	High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled Trial. <i>Circulation</i> , 2021, 143, 2214-2224.	1.6	80
107	An in vivo Model for the Assessment of Acute Fibrinolytic Capacity of the Endothelium. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1242-1248.	1.8	80
108	Validity of a risk-prediction tool for hospital mortality: The Global Registry of Acute Coronary Events. <i>American Heart Journal</i> , 2009, 157, 1097-1105.	1.2	77

#	ARTICLE	IF	CITATIONS
109	Thyroid Disease and Increased Cardiovascular Risk. <i>Thyroid</i> , 2005, 15, 718-724.	2.4	75
110	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. <i>European Heart Journal</i> , 2018, 39, 750-757a.	1.0	72
111	Impact of hospital proportion and volume on primary percutaneous coronary intervention performance in England and Wales. <i>European Heart Journal</i> , 2011, 32, 706-711.	1.0	71
112	Systemic Atherosclerotic Inflammation Following Acute Myocardial Infarction: Myocardial Infarction Begets Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2015, 4, e001956.	1.6	69
113	Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. <i>Journal of the American College of Cardiology</i> , 2019, 73, 121-130.	1.2	69
114	Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 580-589.	3.3	68
115	Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: Further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. <i>American Heart Journal</i> , 2005, 150, 1177-1184.	1.2	67
116	Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events. <i>European Heart Journal</i> , 2010, 31, 667-675.	1.0	63
117	Guideline-indicated treatments and diagnostics, GRACE risk score, and survival for non-ST elevation myocardial infarction. <i>European Heart Journal</i> , 2018, 39, 3798-3806.	1.0	62
118	Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 787-798.	1.6	60
119	Does abdominal obesity have a similar impact on cardiovascular disease and diabetes? A study of 91 246 ambulant patients in 27 European Countries. <i>European Heart Journal</i> , 2009, 30, 3055-3063.	1.0	55
120	10-Year Mortality Outcome of a Routine Invasive Strategy Versus a Selective Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2015, 66, 511-520.	1.2	54
121	2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTEMI-ACS guideline group. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 224-233.	0.4	54
122	A prognostic index to predict long-term mortality in patients with mild to moderate chronic heart failure stabilised on angiotensin converting enzyme inhibitors. <i>European Journal of Heart Failure</i> , 2003, 5, 489-497.	2.9	52
123	Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective. <i>European Heart Journal</i> , 2010, 31, 1328-1336.	1.0	51
124	A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: The GRACE Genetics Study. <i>European Heart Journal</i> , 2010, 31, 1132-1141.	1.0	50
125	Early diagnosis of acute coronary syndrome. <i>European Heart Journal</i> , 2017, 38, 3049-3055.	1.0	50
126	Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2002, 90, 477-482.	0.7	48

#	ARTICLE	IF	CITATIONS
127	Risk Stratification in Non-ST-segment Elevation Acute Coronary Syndromes: Troponin Alone Is not Enough. <i>American Journal of Medicine</i> , 2009, 122, 107-108.	0.6	47
128	Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy. <i>Annals of Internal Medicine</i> , 2013, 158, 861.	2.0	46
129	Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction. <i>European Heart Journal</i> , 2021, 42, 2552-2561.	1.0	45
130	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-CAF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	1.6	44
131	Performance of the GRACE Risk Score 2.0 Simplified Algorithm for Predicting 1-Year Death After Hospitalization for an Acute Coronary Syndrome in a Contemporary Multiracial Cohort. <i>American Journal of Cardiology</i> , 2016, 118, 1105-1110.	0.7	43
132	Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the PRAIS UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK). <i>European Heart Journal</i> , 2004, 25, 2013-2018.	1.0	40
133	Rivaroxaban, an oral direct factor Xa inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 925-937.	1.9	40
134	End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 470-478.	0.9	39
135	Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2243-2250.	1.2	39
136	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020, 141, 1141-1151.	1.6	39
137	Management of acute coronary syndromes: an update. <i>British Heart Journal</i> , 2004, 90, 698-706.	2.2	38
138	Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. <i>American Heart Journal</i> , 2008, 155, 910-917.	1.2	38
139	Randomized Controlled Trial of Dual Antiplatelet Therapy in Patients Undergoing Surgery for Critical Limb Ischemia. <i>Annals of Surgery</i> , 2010, 252, 37-42.	2.1	37
140	Comparison of Acute Coronary Syndrome in Patients Receiving Versus Not Receiving Chronic Dialysis (from the Global Registry of Acute Coronary Events [GRACE] Registry). <i>American Journal of Cardiology</i> , 2012, 109, 19-25.	0.7	36
141	Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: the GRACE Genetics Study. <i>European Heart Journal</i> , 2013, 34, 993-1001.	1.0	35
142	Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2016, 67, 936-947.	1.2	35
143	Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. <i>Heart</i> , 2017, 103, 1168-1176.	1.2	34
144	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease. <i>JAMA Cardiology</i> , 2021, 6, 21-29.	3.0	33

#	ARTICLE	IF	CITATIONS
145	Enhancing the efficacy of delivering reperfusion therapy: A European and North American experience with ST-segment elevation myocardial infarction networks. <i>American Heart Journal</i> , 2013, 165, 123-132.	1.2	31
146	Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. <i>American Heart Journal</i> , 2015, 169, 622-630.e6.	1.2	31
147	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 78, 14-23.	1.2	31
148	Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin. <i>Circulation</i> , 2017, 135, 1001-1003.	1.6	30
149	Major Bleeding in Patients With CoronaryÂor Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1519-1528.	1.2	30
150	Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. <i>Blood Advances</i> , 2021, 5, 1081-1091.	2.5	30
151	New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 301-309.	1.4	29
152	Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2021, 6, 304.	3.0	29
153	Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk. <i>American Heart Journal</i> , 2009, 157, 502-508.	1.2	28
154	A European perspective on improving acute systems of care in STEMI: we know what to do, but how can we do it?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 708-714.	3.3	27
155	Evolving quality standards for large-scale registries: the GARFIELD-AF experience. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 3, qcw058.	1.8	27
156	Evaluation of the impact of the GRACE risk score on the management and outcome of patients hospitalised with non-ST elevation acute coronary syndrome in the UK: protocol of the UKGRIS cluster-randomised registry-based trial. <i>BMJ Open</i> , 2019, 9, e032165.	0.8	27
157	Temporal changes in the management and outcome of Canadian diabetic patients hospitalized for nonâ€“ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2011, 162, 347-355.e1.	1.2	25
158	Effect of <i>PON1</i> Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 250-256.	5.1	25
159	Registries and surveys in acute coronary syndrome. <i>European Heart Journal</i> , 2006, 27, 2260-2262.	1.0	24
160	A cluster randomized trial of objective risk assessment versus standard care for acute coronary syndromes: Rationale and design of the Australian GRACE Risk score Intervention Study (AGRIS). <i>American Heart Journal</i> , 2015, 170, 995-1004.e1.	1.2	23
161	Assessment of Quality Indicators for Acute Myocardial Infarction in the FAST-MI (French Registry of Tj ETQq1 1 0.784314 rgBT /Overl Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	23
162	Frailty assessment and risk prediction by GRACE score in older patients with acute myocardial infarction. <i>BMC Geriatrics</i> , 2020, 20, 102.	1.1	23

#	ARTICLE	IF	CITATIONS
163	An international perspective on acute coronary syndrome care: Insights from the global registry of acute coronary events. <i>American Heart Journal</i> , 2004, 148, S40-S45.	1.2	22
164	Effect of Clopidogrel on the Rate and Functional Severity of Stroke Among High Vascular Risk Patients. <i>Stroke</i> , 2010, 41, 1679-1683.	1.0	22
165	Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: Insights from the Global Registry of Acute Coronary Events. <i>American Heart Journal</i> , 2010, 160, 855-861.	1.2	22
166	Timing of Angiography With a Routine Invasive Strategy and Long-Term Outcomes in Non- σ ST-Segment Elevation Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 191-199.	1.1	22
167	GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study. <i>BMJ Open</i> , 2019, 9, e033283.	0.8	22
168	Association between time of hospitalization with acute myocardial infarction and in-hospital mortality. <i>European Heart Journal</i> , 2019, 40, 1214-1221.	1.0	22
169	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002471.	1.6	22
170	Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. <i>JAMA Network Open</i> , 2020, 3, e200107.	2.8	22
171	Noninvasive, medical management for non- σ ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2008, 155, 397-407.	1.2	20
172	Usefulness of the Admission Electrocardiogram to Predict Long-Term Outcomes After Non-ST-Elevation Acute Coronary Syndrome (from the FRISC II, ICTUS, and RITA-3 [FIR] Trials). <i>American Journal of Cardiology</i> , 2012, 109, 6-12.	0.7	20
173	GRACE risk score: Sex-based validity of in-hospital mortality prediction in Canadian patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2017, 244, 24-29.	0.8	19
174	The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. <i>International Journal of Cardiology</i> , 2019, 278, 7-13.	0.8	19
175	GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 214-227.	1.8	19
176	Long-term outcomes for women versus men with unstable angina/non- σ ST-segment elevation myocardial infarction managed medically without revascularization: Insights from the Targeted platelet Inhibition to clarify the Optimal strategy to medically manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> , 2015, 170, 695-705.e5.	1.2	18
177	Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e181-e189.	0.8	18
178	International comparison of acute myocardial infarction care and outcomes using quality indicators. <i>Heart</i> , 2019, 105, 820-825.	1.2	17
179	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002470.	1.6	17
180	Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2322-2334.	1.9	17

#	ARTICLE	IF	CITATIONS
181	Clopidogrel: an updated and comprehensive review. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 621-631.	1.5	16
182	Impact of an invasive strategy on 5 years outcome in men and women with non-â€œST-segment elevation acute coronary syndromes. American Heart Journal, 2014, 168, 522-529.	1.2	16
183	Machine learning does not improve upon traditional regression in predicting outcomes in atrial fibrillation: an analysis of the ORBIT-AF and GARFIELD-AF registries. Europace, 2020, 22, 1635-1644.	0.7	16
184	Use of Heparins in Non-ST-Elevation Acute Coronary Syndromes. American Journal of Medicine, 2007, 120, 63-71.	0.6	15
185	Spontaneous MI After Non-â€œST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization. Journal of the American College of Cardiology, 2016, 67, 1289-1297.	1.2	15
186	Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 27-35.	1.8	15
187	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. Stroke, 2020, 51, 2901-2909.	1.0	15
188	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. Cardiovascular Research, 2021, 117, 942-949.	1.8	15
189	Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade. Catheterization and Cardiovascular Interventions, 2005, 66, 149-157.	0.7	14
190	Comparative effectiveness of oral anticoagulants in everyday practice. Heart, 2021, 107, 962-970.	1.2	14
191	Have we reached the limit with thrombolytic therapy?. , 1999, 13, 211-216.		13
192	Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome. Heart, 2016, 102, 1396-1402.	1.2	13
193	Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATO): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both. American Heart Journal. 2020. 222. 166-173.	1.2	13
194	Dual or single antiplatelet therapy with anticoagulation?. Lancet, The, 2013, 381, 1080-1081.	6.3	12
195	Use of clinical risk stratification in non-ST elevation acute coronary syndromes: an analysis from the CONCORDANCE registry. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 309-317.	1.8	12
196	The 2020 ESC-ACVC quality indicators for the management of acute myocardial infarction applied to the FAST-MI registries. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 207-215.	0.4	12
197	Effect of Implementing Routine Early Invasive Strategy on One-Year Mortality in Patients With Acute Myocardial Infarction. American Journal of Cardiology, 2010, 105, 36-42.	0.7	11
198	Use of Clopidogrel Post-Coronary Artery Bypass Surgery in Canadian Patients With Acute Coronary Syndromes. Canadian Journal of Cardiology, 2011, 27, 711-715.	0.8	11

#	ARTICLE	IF	CITATIONS
199	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2021, 77, 511-525.	1.2	11
200	Use of the GRACE score by cardiology nurse specialists in the emergency department. <i>British Journal of Cardiac Nursing</i> , 2010, 5, 91-95.	0.0	9
201	Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 825-836.	1.4	9
202	Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry. <i>BMJ Open</i> , 2022, 12, e049933.	0.8	8
203	A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1332-1339.	0.8	7
204	A nationwide causal mediation analysis of survival following ST-elevation myocardial infarction. <i>Heart</i> , 2020, 106, 765-771.	1.2	7
205	Bleeding Events with Antithrombotic Therapy in Patients with Unstable Angina or non-ST-segment Elevation Myocardial Infarction; Insights from a Large Clinical Practice Registry (GRACE). <i>Heart Lung and Circulation</i> , 2008, 17, 5-8.	0.2	6
206	Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 309-317.	0.4	6
207	Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. <i>Heart</i> , 2021, 107, 299-312.	1.2	6
208	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <i>Heart</i> , 2021, 107, 1130-1137.	1.2	6
209	Assessment of Oxygen Supply-Demand Imbalance and Outcomes Among Patients With Type 2 Myocardial Infarction. <i>JAMA Network Open</i> , 2022, 5, e2220162.	2.8	6
210	Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013, 2, 280-291.	0.4	5
211	Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006582.	0.9	5
212	Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction – findings from the LATITUDE-TIMI 60 trial. <i>American Heart Journal</i> , 2022, 243, 147-157.	1.2	5
213	Long-term management of atherothrombosis. <i>British Journal of Hospital Medicine</i> , 2004, 65, 206-209.	0.3	4
214	Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 745-754.	0.4	4
215	Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT). <i>Heart and Vessels</i> , 2022, 37, 1291-1298.	0.5	3
216	Two-year outcomes of UK patients newly diagnosed with atrial fibrillation: findings from the prospective observational cohort study GARFIELD-AF. <i>British Journal of General Practice</i> , 2022, 72, e693-e701.	0.7	3

#	ARTICLE	IF	CITATIONS
217	Is clopidogrel plus aspirin more cost-effective than aspirin alone in high-risk patients with acute coronary syndromes?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 444-445.	3.3	2
218	Clopidogrel in Acute Coronary Heart Disease. <i>The American Heart Hospital Journal</i> , 2005, 3, 234-242.	0.2	2
219	NICE chest pain guidance. <i>Heart</i> , 2010, 96, 1860-1860.	1.2	2
220	Progress from trials to practice. <i>Nature Reviews Cardiology</i> , 2011, 8, 68-70.	6.1	2
221	Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non- σ ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). <i>American Journal of Cardiology</i> , 2018, 122, 1322-1329.	0.7	2
222	In-Hospital Outcomes Associated With Fibrinolytic and Thienopyridine Use in Patients With ST-Segment Elevation Acute Myocardial Infarction. <i>The Global Registry of Acute Coronary Events. Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 501-509.	0.4	1
223	Anticoagulation in atrial fibrillation: the present and the future. <i>JRSM Cardiovascular Disease</i> , 2012, 1, 1-7.	0.4	1
224	External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E513-E522.	0.7	1
225	Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial. <i>Atherosclerosis</i> , 2021, 331, 38-44.	0.4	1
226	Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis. <i>European Heart Journal Digital Health</i> , 2022, 3, 181-194.	0.7	1
227	Antithrombotic agents: Platelet inhibitors, acute anticoagulants, fibrinolytics, and chronic anticoagulants. , 2013, , 332-397.		1
228	Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. <i>Circulation</i> , 2022, 145, 1875-1877.	1.6	1
229	Secondary prevention of MI: current approaches to treatment. <i>The Prescriber</i> , 2013, 24, 23-29.	0.1	0
230	What's new for ESC Congress 2013? (Amsterdam 30th August-4th September 2013). <i>Egyptian Heart Journal</i> , 2013, 65, 141-143.	0.4	0
231	What's new for ESC Congress 2013? (Amsterdam 30th August-4th September 2013). <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2013, 32, 505-507.	0.2	0
232	What's new for ESC Congress 2013? (Amsterdam 30th August-4th September 2013). <i>Revista Portuguesa De Cardiologia</i> , 2013, 32, 505-507.	0.2	0
233	What's new for ESC Congress 2013? (Amsterdam 30 th August - 4 th September 2013). <i>Acta Cardiologica</i> , 2013, 68, 345-346.	0.3	0
234	European Society of Cardiology Congress 2013 highlights. <i>Future Cardiology</i> , 2014, 10, 23-26.	0.5	0

#	ARTICLE	IF	CITATIONS
235	Reply. Journal of the American College of Cardiology, 2016, 67, 1502-1503.	1.2	0
236	Response by Gibson and Fox to Letter Regarding Article, "Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy". Circulation, 2017, 136, 117-117.	1.6	0
237	Response by Fox to Letter Regarding Article, "The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease". Circulation, 2021, 143, e3.	1.6	0
238	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. Journal of the American Heart Association, 2021, 10, e022485.	1.6	0
239	What's new for ESC Congress 2013? (Amsterdam 30th August-4th September 2013). Archivos De Cardiologia De Mexico, 2013, 83, 232-233.	0.1	0
240	Professor Keith AA Fox. European Cardiology Review, 2016, 11, 60.	0.7	0